-Search query
-Search result
Showing 1 - 50 of 177 items for (author: yamamoto & r)
EMDB-44293:
Cryo-EM structure of MraY in complex with analogue 2
Method: single particle / : Hao A, Lee SY
EMDB-44294:
Cryo-EM structure of MraY in complex with analogue 3
Method: single particle / : Hao A, Lee SY
PDB-9b70:
Cryo-EM structure of MraY in complex with analogue 2
Method: single particle / : Hao A, Lee SY
PDB-9b71:
Cryo-EM structure of MraY in complex with analogue 3
Method: single particle / : Hao A, Lee SY
EMDB-38453:
Structure of the SARS-CoV-2 EG.5.1 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
EMDB-38454:
Structure of the SARS-CoV-2 EG.5.1 spike RBD in complex with ACE2
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
PDB-8xlm:
Structure of the SARS-CoV-2 EG.5.1 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
PDB-8xln:
Structure of the SARS-CoV-2 EG.5.1 spike RBD in complex with ACE2
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
EMDB-37648:
SARS-CoV-2 EG.5.1 spike glycoprotein (1-up state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
EMDB-37650:
SARS-CoV-2 EG.5.1 spike glycoprotein (closed-2 state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
EMDB-37651:
SARS-CoV-2 EG.5.1 spike glycoprotein (closed-1 state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
PDB-8wmd:
Structure of the SARS-CoV-2 EG.5.1 spike glycoprotein (closed-2 state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
PDB-8wmf:
Structure of the SARS-CoV-2 EG.5.1 spike glycoprotein (closed-1 state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
EMDB-36724:
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 1)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36726:
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 2)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36727:
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36728:
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (2-up state)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36729:
Structure of SARS-CoV-2 XBB.1.5 spike RBD in complex with ACE2
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-34741:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-34742:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 focused on RBD and NIV-11 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgl:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgm:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-18149:
GBP1 bound by 14-3-3sigma
Method: single particle / : Pfleiderer MM, Liu X, Fisch D, Anastasakou E, Frickel EM, Galej WP
PDB-8q4l:
GBP1 bound by 14-3-3sigma
Method: single particle / : Pfleiderer MM, Liu X, Fisch D, Anastasakou E, Frickel EM, Galej WP
EMDB-33820:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 focused on RBD and NIV-8 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33821:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33822:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33823:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 focused on RBD and NIV-10 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33824:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33825:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33826:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33827:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 focused on RBD and NIV-13 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33828:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33829:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33830:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh6:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh7:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-35622:
SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35623:
SARS-CoV-2 XBB.1 spike glycoprotein (closed-2 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35624:
SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35625:
SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (2-up state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35626:
SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 focused on RBD-ACE2 interface
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8ios:
Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8iot:
Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-2 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8iou:
Structure of SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8iov:
Structure of SARS-CoV-2 XBB.1 spike RBD in complex with ACE2
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-32599:
Cryo-EM structure of tetrameric TLR3 in complex with dsRNA (90 bp)
Method: single particle / : Sakaniwa K, Ohto U
PDB-7wm4:
Cryo-EM structure of tetrameric TLR3 in complex with dsRNA (90 bp)
Method: single particle / : Sakaniwa K, Ohto U, Shimizu T
EMDB-34221:
SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 1)
Method: single particle / : Anraku Y, Sasaki-Tabata K, Kita S, Fukuhara H, Maenaka K, Hashiguchi T
EMDB-34222:
SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 2)
Method: single particle / : Anraku Y, Tabata-Sasaki K, Kita S, Fukuhara H, Maenaka K, Hashiguchi T
Pages: